Drug intelligence / Profile preview

hMPV Y high dose vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

hMPV Y high dose vaccine is an investigational human metapneumovirus (hMPV) vaccine candidate developed by GSK. It is a recombinant protein subunit vaccine designed to elicit an immune response against the hMPV fusion (F) protein, which is critical for viral entry into host cells. The vaccine was evaluated in a Phase 1/2 clinical trial (NCT04144712) as part of a dose-finding study in younger and older adults. In this trial, the "Y" designation refers to a specific investigational formulation or construct of the hMPV antigen, and "high dose" indicates the highest concentration level tested in the study. The program aims to prevent respiratory tract infections caused by hMPV, a significant pathogen in pediatric, elderly, and immunocompromised populations.

Other names
hMPV Y high dose vaccineGSK investigational hMPV vaccine
02

Targets

HMPV F (Human metapneumovirus fusion protein)

Beyond the preview

Go deeper on hMPV Y high dose vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hMPV Y high dose vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call